Guselkumab: Phase II started

MorphoSys said Johnson & Johnson’s Janssen Biotech Inc. unit began a double-blind, placebo-controlled, international Phase II trial to evaluate 100 mg subcutaneous guselkumab given at weeks 0, 4, 12, 20, 28, 36 and 44 in about 150 patients. Patients that qualify for early escape at week 16 will switch to open-label Stelara ustekinumab. At week 24, patients remaining in the placebo arm will receive guselkumab at weeks 24, 28, 36 and 44. ...